Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 2 of 2 entries
Sorted by: Best Match Show Resources per page
Rituximab in combination with CHOP or fludarabine in low-grade lymphoma.

Seminars in oncology

Czuczman MS, Fallon A, Mohr A, Stewart C, Bernstein ZP, McCarthy P, Skipper M, Brown K, Miller K, Wentling D, Klippenstein D, Loud P, Rock MK, Benyunes M, Grillo-López AJ, Bernstein SH.
PMID: 28140090
Semin Oncol. 2002 Feb;29(1):36-40. doi: 10.1053/sonc.2002.30152.

Non-Hodgkin's lymphoma (NHL) is composed of a group of lymphoid malignancies that has been increasing in incidence at an annual rate of 4% to 7% over the last 20 years in both the United States and Europe. The reasons...

Cite
Czuczman MS, Fallon A, Mohr A, et al. Rituximab in combination with CHOP or fludarabine in low-grade lymphoma. Semin Oncol. 2002;29(1):36-40doi: 10.1053/sonc.2002.30152.
Czuczman, M. S., Fallon, A., Mohr, A., Stewart, C., Bernstein, Z. P., McCarthy, P., Skipper, M., Brown, K., Miller, K., Wentling, D., Klippenstein, D., Loud, P., Rock, M. K., Benyunes, M., Grillo-López, A. J., & Bernstein, S. H. (2002). Rituximab in combination with CHOP or fludarabine in low-grade lymphoma. Seminars in oncology, 29(1), 36-40. https://doi.org/10.1053/sonc.2002.30152
Czuczman, Myron S, et al. "Rituximab in combination with CHOP or fludarabine in low-grade lymphoma." Seminars in oncology vol. 29,1 (2002): 36-40. doi: https://doi.org/10.1053/sonc.2002.30152
Czuczman MS, Fallon A, Mohr A, Stewart C, Bernstein ZP, McCarthy P, Skipper M, Brown K, Miller K, Wentling D, Klippenstein D, Loud P, Rock MK, Benyunes M, Grillo-López AJ, Bernstein SH. Rituximab in combination with CHOP or fludarabine in low-grade lymphoma. Semin Oncol. 2002 Feb;29(1):36-40. doi: 10.1053/sonc.2002.30152. PMID: 28140090.
Copy Download .nbib Format: NLM
Rituximab: Ongoing and future clinical development.

Seminars in oncology

Grillo-López AJ, Hedrick E, Rashford M, Benyunes M.
PMID: 28140083
Semin Oncol. 2002 Feb;29(1):105-112. doi: 10.1053/sonc.2002.30145.

Monoclonal antibodies have been used as therapeutic agents for many years. In 1997, rituximab (Rituxan; Genentech, Inc, South San Francisco, CA, and IDEC Pharmaceuticals, San Diego, CA) became the first monoclonal antibody to be approved by the US Food...

Cite
Grillo-López AJ, Hedrick E, Rashford M, et al. Rituximab: Ongoing and future clinical development. Semin Oncol. 2002;29(1):105-112doi: 10.1053/sonc.2002.30145.
Grillo-López, A. J., Hedrick, E., Rashford, M., & Benyunes, M. (2002). Rituximab: Ongoing and future clinical development. Seminars in oncology, 29(1), 105-112. https://doi.org/10.1053/sonc.2002.30145
Grillo-López, Antonio J, et al. "Rituximab: Ongoing and future clinical development." Seminars in oncology vol. 29,1 (2002): 105-112. doi: https://doi.org/10.1053/sonc.2002.30145
Grillo-López AJ, Hedrick E, Rashford M, Benyunes M. Rituximab: Ongoing and future clinical development. Semin Oncol. 2002 Feb;29(1):105-112. doi: 10.1053/sonc.2002.30145. PMID: 28140083.
Copy Download .nbib Format: NLM
Showing 1 to 2 of 2 entries